Matt Veatch

Criterium’s Oncology Consortia members make waves at American Society of Clinical Oncology (ASCO) 2024 annual conference, sharing valuable insights and progress from their innovative research models and clinical trials. https://lnkd.in/e3hnqdze #clinicaltrials #oncology #ASCO24

1

ADAP Advocacy Publishes Final Report for Patient Perspectives on Long-Acting Injectables Comprehensive Report Offers Patient Access Considerations for Injectable HIV Therapies & Injectable HIV Pre-Exposure Prophylaxis WASHINGTON, DC, June 27, 2024 /24-7PressRelease/ -- ADAP Advocacy today, as part of its Long-Acting Injectables (LAIs) Project, published its final report and executive summary on patient perspectives from people living with HIV about approved LAIs medications for the treatment of HIV/AIDS, as well as their HIV-negative counterparts about HIV Pre-Exposure Prophylaxis (PrEP) injectables. The findings yield valuable insights to the barriers being faced by both populations. LAIs are prescription medications designed to either prevent the transmission of HIV or treat HIV over an extended period. These medications can be used to replace daily oral medications. However, anecdotal evidence suggests that access barriers remain. Brandon M. Macsata, CEO of ADAP Advocacy summarized: "Over the last few years we've witnessed some amazing policy work being done on long-acting injectables, but often times it lacked the patient perspective. ADAP Advocacy's Long-Acting Injectables Project starts to fill that gap and the final report being issued today reflects our commitment to addressing the attitudinal, operational, and other associated barriers patients perceive as preventing them from accessing these life-changing products for both the treatment of HIV, as well as the prevention of HIV. The findings from this project serve as a starting point for ADAP Advocacy to conduct additional patient-centric research to learn more about the barriers as well as facilitators faced by patients seeking long-acting injectables. This project's research questions concerned patient treatment preferences, information pathways, utilization, and barriers to access." The final report and executive summary are available online, here https://lnkd.in/e7A_GDCS. ADAP Advocacy's Long-Acting Injectables Project is made possible with support from Gilead Sciences, Merck, and ViiV Healthcare. To learn more about ADAP Advocacy, AIDS Drug Assistance Programs, or its Long-Acting Injectables Project, please email [email protected]. https://lnkd.in/eJZQx3_5

3

The ISPOR Biosimilars Special Interest Group report titled “Mapping HTA Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report” was recently published in the May 2024 issue of Value in Health. This is a follow-up publication to the group’s 2021 report which identified unaddressed issues concerning biosimilar value assessment. The issues which the members uncovered then were brought to health technology assessment (HTA) agencies around the world in semi-structured interviews for their perspectives. Particularly, how do HTA agencies assess biosimilars when the products differ from the originator in available strengths, pharmaceutical forms, and modes of administration? How do HTA agencies proceed with assessments when the originator is not reimbursed at the time of assessment, or a price premium is sought for the biosimilar based on a claim of added value? The study highlights the need for clearer guidance on when and how to conduct HTAs for biosimilars, amongst other recommendations. Congratulations to the ISPOR Biosimilars Special Interest Group for their latest achievement! Read the report here: https://ow.ly/yx6V50RIRoo Read the press release here: https://ow.ly/mgRl50RIRom For more information and to read other relevant publications, visit: https://ow.ly/6luW50RIRon #HTA #ValueAssessment #Biosimilars

47

1 Comment

As we move forward after the FDA decision, it is imperative that stakeholders across the spectrum - researchers, regulators, advocates, and industry leaders - come together with a shared vision to address these challenges. Read the full article here: https://buff.ly/3YQBC99 #MentalHealthAwareness #trauma #ptsd #MDMA #addiction #depression #psilocybin #psychiatry #psychology #psychedelictherapy #psychedelics #medicine #innovation #neuroscience #FDA

2